{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T11:35:38Z","timestamp":1777203338146,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Etelcalcetide, a <jats:sc>d<\/jats:sc>\u2010amino acid peptide, is an intravenous calcimimetic approved for the treatment of secondary hyperparathyroidism. Etelcalcetide binds the calcium\u2010sensing receptor and increases its sensitivity to extracellular calcium, thereby decreasing secretion of parathyroid hormone (PTH) by chief cells. Etelcalcetide and its low\u2010molecular\u2010weight transformation products are rapidly cleared by renal excretion in healthy subjects, but clearance is substantially reduced and dependent on hemodialysis in end\u2010stage renal disease. The effective half\u2010life is 3\u20135 days in patients undergoing hemodialysis 3 times a week. A clinical study using a single microtracer intravenous dose of [<jats:sup>14<\/jats:sup>C]etelcalcetide indicated that 60% of the administered dose was eliminated in dialysate. Etelcalcetide undergoes reversible disulfide exchange with serum albumin to form a serum albumin peptide conjugate that is too large (67 kDa) to be dialyzed, until a subsequent exchange forms etelcalcetide or a low\u2010molecular\u2010weight transformation product. This exchange from albumin is apparent after hemodialysis, when it partially restores etelcalcetide concentrations in plasma. Etelcalcetide has no known risks for drug\u2013drug interactions. In phase 3 studies, 74%\u201375% of hemodialysis patients with secondary hyperparathyroidism who received etelcalcetide achieved a &gt;30% PTH reduction from baseline versus 8%\u201310% of patients who received placebo. The pharmacokinetics and pharmacodynamics of etelcalcetide in hemodialysis patients supports a 5\u2010mg starting dose administered after hemodialysis and uptitration in 2.5\u2010 or 5\u2010mg increments every 4 weeks to a maximum dose of 15\u00a0mg 3 times a week.<\/jats:p>","DOI":"10.1002\/jcph.1090","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T11:20:15Z","timestamp":1521112815000},"page":"717-726","source":"Crossref","is-referenced-by-count":23,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis"],"prefix":"10.1002","volume":"58","author":[{"given":"Benjamin","family":"Wu","sequence":"first","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Melhem","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethlyn","family":"Jaramilla Sloey","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fouqueray","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Benjamin","family":"Hock","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Skiles","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Chow","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06040710"},{"key":"e_1_2_12_3_1","volume-title":"Full prescribing information","author":"Sensipar\u00ae (cinacalcet)","year":"2017"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948050-00002"},{"issue":"2","key":"e_1_2_12_5_1","first-page":"155","article-title":"Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation","volume":"9","author":"Loghman\u2010Adham M","year":"2003","journal-title":"Am J Manag Care."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/104892"},{"key":"e_1_2_12_7_1","unstructured":"European Medicines Agency.Parsabiv\u2122: Summary of Product Characteristics.2016."},{"key":"e_1_2_12_8_1","volume-title":"Full prescribing information","author":"Parsabiv\u2122 (etelcalcetide)","year":"2017"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12106"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.115.098392"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.178194"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-81"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.204834"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft417"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.314"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1031731"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.289"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.068007"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0433-0"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.03.005"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.04.016"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2016.04.002"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-016-9503-z"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19456"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19468"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0550-4"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.460"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.01.016"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2013.05.050"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.1090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T23:21:10Z","timestamp":1694301670000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/jcph.1090"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1090","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]}}}